Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Sandler

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Clinical Lung Cancer|December 9, 2003
Irinotecan in small-cell lung cancer: current data and the status of ongoing trialsAlan Sandler
Oncology (Williston Park, N.Y.)|December 20, 2003
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinibAlan Sandler
Oncology (Williston Park, N.Y.)|May 23, 2002
Irinotecan therapy for small-cell lung cancerAlan Sandler
Oncology (Williston Park, N.Y.)|October 12, 2002
Irinotecan plus cisplatin in small-cell lung cancerAlan Sandler
Oncology (Williston Park, N.Y.)|January 16, 2004
State-of-the-art treatment for advanced non-small-cell lung cancerAlan Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Bevacizumab in non small cell lung cancerAlan Sandler
Drugs & Aging|July 3, 2002
Lung cancer in the elderly: current and future chemotherapeutic optionsStuart Hinton, Alan Sandler
Cancer Journal (Sudbury, Mass.)|July 11, 2007
Lung cancer adjuvant therapyLeora Horn, Alan Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathwaysAlan Sandler, Roy Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancerLeora Horn, Alan Sandler
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Clinical Lung Cancer|December 9, 2003
Irinotecan in small-cell lung cancer: current data and the status of ongoing trialsAlan Sandler
Oncology (Williston Park, N.Y.)|December 20, 2003
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinibAlan Sandler
Oncology (Williston Park, N.Y.)|May 23, 2002
Irinotecan therapy for small-cell lung cancerAlan Sandler
Oncology (Williston Park, N.Y.)|October 12, 2002
Irinotecan plus cisplatin in small-cell lung cancerAlan Sandler
Oncology (Williston Park, N.Y.)|January 16, 2004
State-of-the-art treatment for advanced non-small-cell lung cancerAlan Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Bevacizumab in non small cell lung cancerAlan Sandler
Drugs & Aging|July 3, 2002
Lung cancer in the elderly: current and future chemotherapeutic optionsStuart Hinton, Alan Sandler
Cancer Journal (Sudbury, Mass.)|July 11, 2007
Lung cancer adjuvant therapyLeora Horn, Alan Sandler
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathwaysAlan Sandler, Roy Herbst
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancerLeora Horn, Alan Sandler
Pageof 9